Latest Treatment News in Neuroendocrine Tumours

Expansion of public funding for Lutathera in Ontario to now include pNETs patients

Luththera: Funding update for radionuclide therapy for pancreatic neoroendocrine tumours (pNETs). Effective November 7, 2023, Ontario Health will fund the use of Lutathera to treat eligible pancreatic neuroendocrine tumour (pNETs) [...]

By |2023-11-10T16:36:25-05:00November 10th, 2023|Treatment News|Comments Off on Expansion of public funding for Lutathera in Ontario to now include pNETs patients

Update on Lutathera pCPA Negotiations for pNETs

One step closer to access to Lutathera for pNETs patients! The pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with Advanced Accelerator Applications for Lutathera (lutetium 177 dotatate) in pNETs  concluded on [...]

By |2023-10-27T00:14:12-04:00October 27th, 2023|Treatment News|Comments Off on Update on Lutathera pCPA Negotiations for pNETs

Somatuline Motorized Delivery Device – Press Release

Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience. New electronic autoinjector is designed to improve patient experience for [...]

By |2023-04-09T15:37:34-04:00April 9th, 2023|Treatment News|Comments Off on Somatuline Motorized Delivery Device – Press Release

Temozolomide Access in Ontario

CNETS is pleased to share the news that the oral chemotherapy drug, temozolomide, often used in combination with capecitabine, known as the CAPTEM regimen, is now more accessible to [...]

By |2021-07-07T21:48:16-04:00July 6th, 2021|Treatment News|Comments Off on Temozolomide Access in Ontario

Lutathera Funded in Saskatchewan

As of June 1, 2021, Lutathera is now available in Saskatchewan. The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced [...]

By |2021-07-06T18:30:28-04:00July 6th, 2021|Treatment News|Comments Off on Lutathera Funded in Saskatchewan

LUTATHERA Funded In British Columbia

CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication. The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal Peptide [...]

By |2021-05-30T15:16:40-04:00March 8th, 2021|Treatment News|Comments Off on LUTATHERA Funded In British Columbia

LUTATHERA® Funded in Ontario

Radiopharmaceutical cancer treatment Lutathera® now available to Ontario patients with midgut neuroendocrine tumours (NETs). The Ontario funding criteria covers the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut NETs [...]

By |2020-10-10T14:14:05-04:00October 10th, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Ontario

LUTATHERA® Funded in Quebec

As of September 30, 2020, the Québec Ministry of Health and Social Services has listed Lutathera on the Liste de Médicaments – Établissements. Lutathera will be reimbursed for GEP-NETs patients [...]

By |2020-10-03T15:46:51-04:00October 3rd, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Quebec

LUTATHERA® Funded in Nova Scotia

As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut [...]

By |2020-09-06T16:03:58-04:00September 4th, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Nova Scotia
Go to Top